Management of Multiple Sclerosis Multiple sclerosis (MS) is a chronic immune-mediated disease of the central nervous system (CNS). The prevalence of MS is estimated to be between 15 and 145 per 100,000 population in the United States. It is believed that approximately 1 million persons worldwide are affected by MS. The disease is ... Article
Article  |   June 01, 2000
Management of Multiple Sclerosis
Author Affiliations & Notes
  • Francois A. Bethoux, MD
    The Cleveland Clinic Foundation
Article Information
Articles
Article   |   June 01, 2000
Management of Multiple Sclerosis
SIG 2 Perspectives on Neurophysiology and Neurogenic Speech and Language Disorders, June 2000, Vol. 10, 4-11. doi:10.1044/nnsld10.2.4
SIG 2 Perspectives on Neurophysiology and Neurogenic Speech and Language Disorders, June 2000, Vol. 10, 4-11. doi:10.1044/nnsld10.2.4
Multiple sclerosis (MS) is a chronic immune-mediated disease of the central nervous system (CNS). The prevalence of MS is estimated to be between 15 and 145 per 100,000 population in the United States. It is believed that approximately 1 million persons worldwide are affected by MS. The disease is usually diagnosed between the ages of 20 and 40 years and is characterized by a high level of objective and subjective morbidity, with a relatively low level of mortality, particularly in the first years. The most striking characteristics of MS are the heterogeneity of clinical presentation and the variability of the disease course. These features explain the need for individualized management and for rigorous methodology when designing clinical trials. Recent advances in the understanding of the neuropathology of MS, the development of imaging techniques, and the advent of therapies aimed at altering the course of the disease (called disease-modifying therapies) have resulted in considerable changes in the management of patients with MS.
First Page Preview
First page PDF preview
First page PDF preview ×
View Large
Become a SIG Affiliate
Pay Per View
Entire SIG 2 Perspectives on Neurophysiology and Neurogenic Speech and Language Disorders content & archive
24-hour access
This Issue
24-hour access
This Article
24-hour access
We've Changed Our Publication Model...
The 19 individual SIG Perspectives publications have been relaunched as the new, all-in-one Perspectives of the ASHA Special Interest Groups.